Keros Therapeutics files prospectus supplement for up to $350M at-the-market stock offering

Keros Therapeutics, Inc.

Filed prospectus supplement on June 17, 2024 to sell up to $350 million of common stock via ATM program.
Leerink Partners acts as sales agent, earning a commission of up to 3.0% of gross proceeds.
Sales may be made directly on the Nasdaq Global Market; company not obligated to sell any shares.
Original sales agreement dated May 3, 2021; shelf registration statement effective May 3, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.